Sanofi, a French pharmaceutical company, will demolish a plant it spent about $118 million to build and never even used.
A Sanofi spokesperson confirmed that the French drugmaker is preparing to put the wrecking ball to a plant at its R&D site in Montpellier, France. The facility was supposed to produce large batch APIs for clinical trials when envisioned in the early 2000s, but was no longer relevant when the €107 million ($118.5 million) “tool” was completed in 2011. It has set idle since.
Meanwhile, Sanofi has been expanding its biologics manufacturing capabilities but this time around it shares the risk and cost of plants with partners. In February, it announced it and Swiss CDMO Lonza would jointly build a €270 million ($286.3 million) plant at Lonza’s site in Visp, Switzerland.